Table 3.

Adherence

DMT	PDC	PDC > 0.8
Ocrelizumab	0.99 ± 0.24	155/177	88%
Alemtuzumab	1.02 ± 0.08	15/15	100%
Natalizumab	0.93 ± 0.17	41/51	80%
Cladribine	1.14 ± 0.37	7/7	100%
Fingolimod	0.89 ± 0.27	90/125	72%
Teriflunomide	1.09 ± 0.18	54/57	94%
Dimethyl fumarate	0.62 ± 0.53	50/114	43%
Interferon beta1a im	1.04 ± 0.35	5/7	71%
Interferon beta1b	0.83 ± 0.12	1 /2	50%
Glatiramer acetate	0.98 ± 0.27	9/11	81%
Peg-interferon beta1a	0.95 ± 0.28	11/18	61%
Interferon beta1a sc	1.01 ± 0.27	16/21	76%

Table shows the proportion of days covered (PDC) for each DMT, calculated as the total days covered during 1 year divided by 365 days of follow-up (as from current regulatory indications), for each ITP. The number and percent of patients with PDC above 80% is also reported